Human immunodeficiency virus type 1 (HIV-1) genetic diversity is reflected by three groups (M, N, and O), at least nine group M clades, and 14 circulating recombinant forms (16) . Given the high error rate of its reverse transcriptase and the potential for coinfecting clades to recombine, HIV has great potential for diversifying (18) . Currently, clade C viruses account for 56% of all global HIV infections (2) .
Rapidly expanding within regions with a high prevalence of HIV, such as sub-Saharan Africa, HIV clade C is considered to be a more virulent circulating form than other clades (2, 18) . In general, clade C long terminal repeats (LTRs) contain three NF-B sites compared to clade B LTRs, which contain only two, a characteristic which was postulated to enhance clade C proviral transcriptional activation (10) . Indeed, the level of tumor necrosis factor alpha stimulation correlated with the number of NF-B sites, indicating some difference among HIV LTRs (5, 20) .
To date, numerous HIV isolates have been cloned and sequenced (3, 7-9, 11-15, 17-19, 21, 22) . Among these, only Indie-C1 (9) and MJ4 (12) are infectious clade C viruses that use CCR5 as coreceptor. Indie-C1 is a primary Indian isolate (9) , and MJ4 is a chimeric infectious clone, containing the 96MOLE1 envelope and the replication-incompetent backbone of 96BW06. 96MOLE1 and 96BW06 were originally isolated from anonymous infected donors in Botswana (12) . The HIV disease stages of the source persons for both Indie-C1 and MJ4 are unknown (9, 12) .
We constructed a replication-competent, infectious proviral DNA clone of a pediatric HIV clade C isolate, HIV1084i. This virus was recovered by cocultivation from a 4-month-old, HIVpositive Zambian infant whose umbilical cord blood had been HIV negative by PCR. HIV-negative donor peripheral blood mononuclear cells (PBMCs) were purified by using Lymphoprep (Life Technologies, Grand Island, N.Y.) and propagated in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) and 5 g of phytohemagglutinin (PHA) (Sigma, St. Louis, Mo.)/ml for 40 h. Then, the infant's PBMCs were cocultured with an equal number of PHA-stimulated PBMCs from the seronegative donor to a combined final concentration of 2 ϫ 10 6 cells/ml. Equal numbers of fresh uninfected PHA-stimulated PBMCs were added to the culture weekly. Virus production was monitored by measuring HIV-1 p24 antigen levels with a commercial enzyme-linked immunosorbent assay (ELISA) kit (Beckman Coulter, Somerset, N.J.).
Genomic DNA from the cocultivated PBMCs served as template for the following PCRs. A 5.4-kb fragment extending from the 5Ј LTR through the vpr open reading frame was amplified by using Expand High Fidelity Taq polymerase (Roche, Alameda, Calif.) and the following Indie-C1-based primers: 5Ј-LTR-NotI (primer 1 in Fig. 1 : 5Ј-AATGCGGCCGCCTGGA AGGGTTAATTTACTCCAAGAAAAGGCAAG-3Ј) and 5Ј-reverse-AscI (primer 2 in Fig. 1 : 5Ј-GTCTATGAAACATAT GGCGCGCCTTGGACAGGAGTCG-3Ј) (Invitrogen, Carlsbad, Calif.). Similarly, a 4.3-kb fragment extending from the vpr open reading frame beyond the 3Ј LTR was amplified using the following Indie-C1-based primers: 3Ј-forward-AscI (primer 3 in Fig. 1 : 5Ј-CGACTCCTGTCCAAGGCGCGCCATATGT TTCATAGAC-3Ј) and 3Ј-LTR-NotI (primer 4 in Fig. 1 : 5Ј-CGCGCGGCCGCACTGACTAAAAGGGTCTGAGGGAT CTCTAGTTAC-3Ј) (Invitrogen). As indicated, NotI restriction sites were added upstream of the 5Ј LTR and downstream of the 3Ј LTR, while an AscI restriction site was introduced in the vpr open reading frame using the following nucleotide changes: G5672C, A5674C, T5675G, and A5676C.
The amplicons were individually cloned into pCR 2.1-Topo TA cloning vectors (Invitrogen) and expanded through transformation of chemically competent Top 10 Escherichia coli cells (Invitrogen). Plasmid DNA was extracted with the QIAprep Spin Miniprep kit (QIAGEN, Valencia, Calif.); fulllength proviruses were reconstructed from the subgenomic segments. Briefly, all vectors were digested with XhoI and AscI (New England Biolabs, Beverly, Mass.), and the 5Ј and 3Ј vectors (vectors B and C in Fig. 1 ) were subsequently treated with alkaline phosphatase. The 3Ј insert (vector D in Fig. 1 ) was treated with SpeI, and the 5Ј insert (vector A in Fig. 1 ) was left unmodified. Overnight ligation of gel-purified vectors A and C (or vectors D and B) ( Fig. 1 ) with T4-DNA ligase was followed by transformation of chemically competent Top 10FЈ E. coli cells (Invitrogen).
Next, 293T cells grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS (Sigma) were transfected with 6 g of HIV1084i DNA by calcium phosphate precipitation (Promega, Madison, Wis.).
pIndie-C1 served as a positive control, and pIRES-hrGFP (Life Technologies) served as a negative control. Cell-free supernatants that were positive for p24 Gag ELISA (Beckman Coulter) 72 h posttransfection were used to infect human PBMCs. Supernatants were monitored every 3 days until day 15 for p24 Gag production; HIV1084i replication peaked on day 9 (data not shown).
Next, we assessed the sensitivity of HIV1084i to zidovudine (AZT). Half of the wells containing PBMCs were pretreated with 10 M AZT (Sigma) for 30 min at 37°C. HIV1084i or Indie-C1 were added and incubated overnight at 37°C; controls included uninfected PBMCs cultured with AZT. The next day, cells were washed three times with medium and resuspended in RPMI medium supplemented with 15% FBS with or without 10 M AZT. Supernatants were collected at regular intervals. Wells containing AZT did not produce p24. PBMCs from three independent donors supported replication of HIV1084i (Fig. 2 and data not shown) , and HIV1084i env-specific primers were used to amplify a 700-bp fragment from genomic DNA of infected PBMCs (data not shown).
To determine coreceptor usage, the following U87.CD4 cells expressing one of the following chemokine coreceptors were used (1, 6): CCR1, CCR2b, CCR3, CXCR4, or CCR5, as well as Ghost.CD4 cells expressing the CCR5, BOB, or BONZO coreceptors (National Institutes of Health AIDS Research and Reference Reagent Program, Rockville, Md.). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and infected with HIV1084i viral stock in polybrene (Sigma). Supernatants were collected on days 3, 5, 7, and 10 for p24 Gag titration. HIV1084i replicated only in the U-87.CD4.CCR5 cells (p24 Gag levels, Ͼ1 ng/ml; data not shown).
The infectious molecular clone of HIV1084i was sequenced by using a primer walking method and more than 50 pIndie-C1-derived primers. Individual contiguous stretches of proviral DNA were assembled using the DNASIS program. HIV1084i is 9,665 bp in length, and all reading frames for major and accessory genes are open. Both LTRs are flanked by NotI restriction sites, and vpr contains an AscI restriction site not found in pIndie-C1. Although Vpr contained two nonconservative mutations (D52A and T53P), HIV1084i productively infected PBMCs from three independent donors.
To perform phylogenetic analysis, a multiple sequence alignment was carried out on gag, pol, and env and the expected Vpu and Rev sequences with Clustal X (version 1.81) (Fig. 3) . Comparison of HIV1084i gag, pol, and env genes with those of other HIV isolates placed HIV1084i within the clade C lineage, despite having origins in Zambia, where the dominant circulating HIV forms include clades C, D, and G; group HIV1084i had no evidence of interclade recombination; however, HIV1084i pol and env clustered closely with AF110963, a Botswana isolate (Fig. 3B and C) , while HIV1084i gag clustered with two Indian and two Chinese isolates (AF067254 and AB023804 and AF286229 and AF286230, respectively) (Fig.  3A) . It is important to note that this differential clustering could not have resulted from our cloning strategy (Fig. 1) , as the entire gag-pol region was contained within the 5Ј half that was initially amplified en bloc using primers located within the 5Ј LTR and in vpr at the AscI restriction site (nucleotides 5670 to 5671). Thus, the recombination breakpoint region within the gag-pol overlap region (nucleotides 2058 to 2253) was left untouched. We conclude that the differential clustering of gag and pol within HIV1084i probably resulted from an intraclade recombination event.
The predicted HIV1084i Rev and Vpu sequences revealed several clade C signature sequences. Vpu contained the ARVDY sequence, a 5-amino-acid (aa) extension upstream of the amino-terminal transmembrane domain (Fig. 3D) . This extension was also present in Vpu of MJ4, a hybrid constructed from two distinct African clade C isolates; however, it was absent from Indie-C1 and the non-C isolates examined, as reported previously (19) . Furthermore, the clade C-specific LRLL motif appeared upstream of the Vpu C terminus for HIV1084i, MJ4, and Indie-C1 but was absent from all other non-C infectious clones. Phylogenetic analysis placed HIV1084i Vpu into the clade C cluster as a branch off the MJ4 lineage (Fig. 3D) .
Compared to the clade B reference, HBX-2R, the Rev aa sequences for HIV1084i, MJ4, and Indie-C1 contained premature stop codons, which shortened HIV1084i and MJ4 by 9 aa and Indie-C1 by 16 aa (Fig. 3E) . Phylogenetic analysis of the HIV1084i Rev localized it within the clade C cluster, as a branch of the MJ4 lineage (Fig. 3E) .
Next, we surveyed the number of NF-B binding sites found in 16 distinct clade C LTRs. HIV1084i and eight other LTRs contained three NF-B binding sites, two of which contained the sequence GGGACTTTCC, while the third site's sequence was GGGGCGTTCC. The remaining seven LTRs, including that of MJ4 (12) , displayed two of the three characteristic NF-B binding sites with the sequence GGGACTTTCC.
In conclusion, we have constructed an infectious molecular clade C clone, HIV1084i, which was replication competent in PBMCs from three different donors, was exclusively R5 tropic, and did not induce syncytia. Isolated from a Zambian infant whose infection was first detected by PCR at 4 months of age, HIV1084i represents a recently transmitted virus. Consistent with recent transmission, many viral isolates recovered from the 1084 mother-infant pair had uncharacteristically close env sequence homology (25) . As a recently transmitted virus, HIV1084i will be a useful tool for testing novel passive (24) and active vaccine strategies.
Nucleotide sequence accession number. The nucleotide sequence of HIV1084i is available through GenBank (no. AY805330).
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